35. -5. 3

杉

Fig.1
PRIOR ART




Fig.2




Fig.3
PRIOR ART




Fig.4
PRIOR ART

	_INPUT ENTITY	9
	RESOURCES	5
ACTIVITY (3a)	ACTIVITY	3b
	ACTIVITY	<u>3</u> c
	CONTROL	7

Fig.5




Fig.6

T R

Fig.7

T

R





Fig.9



EXERCISE RELATIVE TO BODY SYSTEM


CARDIOVASCULAR RESPIRATORY MUSCULAR


R


M


M


M












EXTERNAL GOALS 45 TIME 23 53 23 53 LEVEL 1 / LEVEL 2 LEVEL 3 / LEVEL 4

Fig.17

Fig.18









Fig.20











Fig.24






Fig.26





Fig.27

ξ

TR	TRIAL HISTORY FOR DRUG DEVELOPMENT (SAMPLE 10)				
	JAN FEB MAR APR MAY JUNE	< 10LY <	AUG >	SEPT	OCT
TRIAL A	FROM 1.5 TO 2.3 STARTS AT 1.00				
TRIAL B	START RANGE GOES FROM 0.1 TO 4.9 IN DATA SET 3.16 AVG RANGES FROM 3 TO 4			_ ~ ~ ~ ~ ~ ~ ~	
TRIAL C	START RANGE GOES FROM 1.1 TO 9.2 IN DATA SET	2 IN DATA SET 27 AVG ANGES FROM 0 TO 2.2			
TRIAL D	STARTRA	TO 9.1 IN DATA SI 1.94, FROM	TA SET 1.94 AVG RANGES FROM 1.0 TO 3.3		
1	STARTS 6.9	rs 6.9			

ζ,



Fia.2




Fig.29


RISKS

LEVEL 3

LEVEL 2

LEVEL 1










RISKS

LEVEL 1








PROJECTS A, B, C 1999





LEVEL 2

LEVEL 1

LEVEL 3

